EVENTS & PRESENTATIONS
Join us as we share our achievements and vision at global events
Upcoming Events
Corporate Presentation
Presentations
Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects
October 2025, IDWeek, Atlanta, GA
Preliminary Results of the First-in-Human Phase 1 Trial of AIC468: A Novel Antisense Oligonucleotide that Targets BK-Virus Transcripts
October 2025, IDWeek, Atlanta, GA
Pharmacokinetics of AIC468 in Healthy Volunteers from a First-in-Human Phase 1 Clinical Trial: A Novel Antisense Oligonucleotode Targeting BK Virus Transcripts
August 2025, WTC, San Francisco, CA
Pritelivir for Resistant HSV Infections: Phase 3 Progress and Expanding Therapeutic Horizons
July 2025. STIV & HIV World Congress
Treatment of Herpes Simplex Encephalitis with the Helicase-Primase Inhibitor Pritelivir in an Immunocompromised Patient
April 2025. ECCMID, Vienna
April 2024. ECCMID, Barcelona
June 2024, ATC, Philadelphia
Aicuris presents novel data on its candidate AIC468, an antisense oligonucleotide for treatment of BKV infections
Aicuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th
Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference. With Senior Management from both our German headquarters and US subsidiary joining, we are looking forward to starting off the new year 2024 with an inspirational week of meetings and the opportunity to connect to stakeholders of the biotech industry. If you are interested in discussing novel antiviral therapy options for patients with a weakened immune system, as well as exciting business opportunities, ask for a meeting via info@aicuris.com.